Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Arvind Dasari et al.|Annals of Oncology|2018Cited by 239
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid TumorsKaysia Ludford, Michael J. Overman, Won Jin Ho et al.|Journal of Clinical Oncology|2023Cited by 193
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Scott Kopetz, Shailesh Advani et al.|PLoS ONE|2017Cited by 88
Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice surveyKathryn A. Mraz, Mev Dominguez–Valentin, Rachel Hodan et al.|Frontiers in Oncology|2023Cited by 9
Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the Americas on Inherited Gastrointestinal CancerRachel Hodan, Kimberly Perez, Linda Rodgers et al.|Journal of Genetic Counseling|2022Cited by 4